sub News Events

Hero

Press Releases

Press Releases

Royalty Pharma to Announce Second-Quarter 2021 Financial Results on August 11, 2021

NEW YORK, NY, July 19, 2021 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter of 2021 financial results on Wednesday, August 11, 2021 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m.

Royalty Pharma Declares Third-Quarter 2021 Dividend

NEW YORK, NY, July 16, 2021 – The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2021 of $0.17 per class A ordinary share. The dividend will be paid on September 15, 2021, to shareholders of record at the close of business on

Royalty Pharma Announces Pricing of $1.3 Billion of Senior Unsecured Notes, Including $600 Million Social Bond

NEW YORK, NY, July 15, 2021 – Royalty Pharma plc (Nasdaq: RPRX) announced today that it has priced an offering of $1.3 billion of senior unsecured notes, comprised of the following (collectively, the “Notes”): $600 million of 2.15% Senior Notes due 2031 (the “Social Bonds”)

Royalty Pharma to Present at Upcoming Investor Conferences

NEW YORK, NY, June 7, 2021 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of June: Goldman Sachs Global Healthcare Conference on Wednesday, June 9 at 3:50 p.m. Bank of America Napa Biopharma

Royalty Pharma Announces $2.025 Billion Strategic Funding Partnership with MorphoSys

NEW YORK, NY, and PLANEGG, GERMANY, June 2, 2021 – Royalty Pharma plc (Nasdaq: RPRX) and MorphoSys AG (FSE: MOR; Nasdaq: MOR) today announced a $2.025 billion strategic funding partnership as part of MorphoSys’ $1.7 billion acquisition of Constellation Pharmaceuticals

Royalty Pharma Reports First Quarter 2021 Results

NEW YORK , May 11, 2021 - Double-digit growth in Net cash provided by operating activities (GAAP) and Adjusted Cash Flow; Announced transactions of up to $787 million in 2021, including $582 million in upfront payments; Increased Adjusted Cash Receipts guidance for 2021

Royalty Pharma to Present at Upcoming Investor Conferences

NEW YORK, NY, May 7, 2021 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May: Bank of America 2021 Healthcare Conference on Wednesday, May 12 at 9:30 a.m. EDT 7th Annual Truist Securities Life Sciences

Royalty Pharma to Announce First-Quarter 2021 Financial Results on May 11, 2021

NEW YORK, NY, April 21, 2021 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2021 financial results on Tuesday, May 11, 2021 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m.

Royalty Pharma Announces Strategic Alliance with MSCI to Launch Life Sciences Indexes

NEW YORK, NY, April 21, 2021 – Royalty Pharma plc (Nasdaq: RPRX) today announced a collaboration with MSCI Inc. (NYSE: MSCI), a leading provider of critical decision support tools and services for the global investment community, to expand MSCI’s thematic index suite with the launch of new indexes

Royalty Pharma Declares Second-Quarter 2021 Dividend

NEW YORK, NY, April 15, 2021 - The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2021 of $0.17 per class A share. The dividend will be paid on June 15, 2021, to shareholders of record at the close of business on May 20, 2021.
Displaying 1 - 10 of 75